Why diagnosis codes alone fall short for long COVID surveillance
When our client, a global pharmaceutical company, set out to better understand long COVID pathways,...
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million people in the United States. Yet for many patients, the path to diagnosis spans years, sometimes decades. Symptoms appear one at a time. Specialists...
When our client, a global pharmaceutical company, set out to better understand long COVID pathways,...
AI is playing a growing role in real-world evidence, but not all AI serves the same purpose. Two...
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million...
"Healthcare audience targeting has changed fast, and expectations have climbed even faster." As...
AI is rapidly reshaping how real-world data (RWD) is generated and analyzed across healthcare...
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...
Healthcare marketing has reached an inflection point and for years, success was defined by reach:...
When our client, a global pharmaceutical company, set out to better understand long COVID pathways, they had a central question to answer:how much of the long COVID population are we missing if we rely on diagnosis codes alone?